RAZE THERAPEUTICS INC has a total of 16 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2015. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and United States. Its main competitors in its focus markets organic fine chemistry and pharmaceuticals are CTXT PTY LTD, MOREPEN LAB LTD and BOUCHARA EMILE.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 8 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | United States | 4 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Acyclic or carbocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Mainolfi Nello | 15 |
#2 | Saiah Eddine | 7 |
#3 | Moyer Mikel P | 5 |
#4 | Lecci Cristina | 3 |
#5 | Pace Robert David Matthew | 3 |
#6 | Tye Heather | 3 |
#7 | Vile Julia | 3 |
#8 | Moyer Mikel | 2 |
Publication | Filing date | Title |
---|---|---|
WO2018106636A1 | Shmt inhibitors and uses thereof | |
WO2017156181A1 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
US2019071400A1 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
WO2017156177A1 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
US2019071431A1 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
US2018370972A1 | Caffeine inhibitors of mthfd2 and uses thereof | |
WO2017023894A1 | Mthfd2 inhibitors and uses thereof | |
WO2016040449A1 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |